Treatment of Discoid Lupus Erythematosus During Pregnancy or Breastfeeding
Active discoid lupus erythematosus (DLE) requires careful, evidence-based treatment selection when the patient is pregnant or breastfeeding, where therapeutic choices must account for both disease control and safety for the developing fetus or infant.
Clinical Scenario
This protocol covers active DLE in patients who are pregnant or breastfeeding. Both situations call for specific treatment decisions to effectively manage cutaneous disease while maintaining safety for the mother and child.
Treatment Approach
The first-line approach centres on hydroxychloroquine, with a low-dose systemic corticosteroid potentially added in some cases — the complete protocol, including decision criteria and clinical guidance, is available below.
References
In active disease during pregnancy or breastfeeding, we recommend HCQ as first line treatment for CLE at usual dosage.
We recommend continuing the maintenance of HCQ treatment during pregnancy, but we also recommend switching from CQ to HCQ in this period.
We recommend that systemic corticosteroids (prednisone and methylprednisolone) should be given in a dosage of not more than 10 - 15 mg per day during pregnancy or breastfeeding.
View source ↗